Do Not Coadminister
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Doravirine/Lamivudine/ Tenofovir-DF (DOR/3TC/TDF)
Quality of Evidence:
Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, Delstrigo contains lamivudine and tenofovir-DF and should not be administered products containing emtricitabine or additional tenofovir-DF.
Delstrigo is a complete regimen for the treatment of HIV-1 infection; therefore, Delstrigo should not be administered with other antiretroviral medicinal products. Doravirine/lamivudine/tenofovir disoproxil must not be co-administered with medicinal products containing tenofovir disoproxil. Coadministration of tenofovir disoproxil (300 mg once daily) and doravirine (100 mg single dose) decreased doravirine AUC, Cmax and C24 by 5%, 20% and 6%, respectively.
Delstrigo Summary of Product Characteristics, Merck Sharp & Dohme Ltd, November 2018.
Because Delstrigo is a complete regimen for the treatment of HIV-1 infection, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended.
Delstrigo US Prescribing Information, Merck & Co Inc, August 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking